Biosimilars makers in Canada to launch patient support programme

Biosimilars/General | Posted 11/01/2019 post-comment0 Post your comment

Biosimilars Canada, an association representing Canada’s biosimilar makers, announced on 22 November 2018 that it had chosen pharmaceutical service provider Innomar Strategies to be the preferred provider for the association’s Patient Support Program (PSP) platform.

Patient MD002316 V13C05

The Biosimilars Canada PSP platform will provide patient support services for Biosimilars Canada members that can be customized to meet the individual needs of the therapy, the biosimilar sponsor and payers.

According to Jim Keon, President of Biosimilars Canada, the country ‘is recognized internationally as having high barriers to market entry for sponsors of biosimilars, in part because many products administered in hospitals in other jurisdictions are administered in private clinics in Canada and require extensive services to support the patient in their journey’. This is where the association hopes that its PSP platform can ‘be an important solution in ensuring biosimilar sponsors can provide high quality patient support services required by payers, physicians and patients while providing value to the Canadian healthcare system’.

To date, Health Canada has approved 10 biosimilars [1]. Although uptake has been slow so far, Biosimilars Canada expects the use of biosimilars to increase more rapidly in 2019 and beyond ‘as new biosimilars are launched and benefit designs and coverage policies continue to evolve to optimize the use of biosimilar treatments’.

Biosimilars in Canada help ‘to enhance competition, improve access to biologic medicines, and contribute to the financial sustainability of healthcare systems’, according to Michel Robidoux, Chair of Biosimilars Canada and President/General Manager of Sandoz Canada.

‘As more biosimilars come into the market, patients will need services built around these products to support them with their illness. By utilizing a centralized Patient Support Program model, healthcare providers, manufacturers and patients will experience efficiencies, while still having a best-in-class experience’, said Kevin West, Vice President of Innomar Strategies.

Biosimilars Canada is planning to launch its patient support platform in 2019.

Related article
Green Shield Canada preferentially lists biosimilars

1. GaBI Online - Generics and Biosimilars Initiative. Biosimilars approved in Canada []. Mol, Belgium: Pro Pharma Communications International; [cited 2019 Jan 11]. Available from:

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2019 Pro Pharma Communications International. All Rights Reserved.

Source: Biosimilars Canada

comment icon Comments (0)
Post your comment
Related content
Biosimilars of pembrolizumab
Cancer image015
Biosimilars/General Posted 14/10/2022
EMA calls for biosimilar interchangeability across the EU
01 AA007239
Biosimilars/General Posted 23/09/2022
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010